Valuation: Glenmark Pharmaceuticals Limited

Market Cap 628B 6.61B 5.79B 5.33B 4.94B 9.38B 9.53B 63.94B 24.87B 310B 24.82B 24.29B 1,070B P/E 2026
44.2x
P/E 2027 * 27.3x
Enterprise Value 588B 6.2B 5.42B 5B 4.63B 8.8B 8.94B 59.94B 23.31B 290B 23.27B 22.76B 1,003B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.54x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day-1.82%
1 week+0.88%
Current month+0.88%
1 month+2.65%
3 months+5.18%
6 months+5.23%
Current year+9.26%
1 week 2,142.8
Extreme 2142.8
2,293.9
1 month 2,101
Extreme 2101
2,293.9
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 661
Extreme 661
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 85 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%+0.88%+19.55%+222.63% 6.73B
-0.80%+1.38%+12.40%+82.31% 48.12B
-3.08%+3.29%+65.80%+113.96% 37.36B
-1.38%-2.29%-5.21%+40.28% 12.36B
-0.43%+3.18%+14.94%+97.17% 12.12B
+0.38%+4.19%+34.19%+123.08% 9.14B
-2.20%-0.91%+19.15%+43.83% 7.21B
+1.24%+4.23%+58.03%-1.50% 7.14B
-7.00%+12.89%-22.31%+10.09% 6.35B
-1.08%-4.20%+23.39%+130.69% 4.36B
Average -1.62%+1.89%+21.99%+86.25% 15.09B
Weighted average by Cap. -1.60%+3.01%+27.36%+89.19%

Financials

2026 2027 *
Net sales 153B 1.61B 1.41B 1.3B 1.21B 2.29B 2.33B 15.6B 6.07B 75.56B 6.06B 5.93B 261B 167B 1.76B 1.54B 1.42B 1.31B 2.5B 2.54B 17.01B 6.61B 82.37B 6.6B 6.46B 285B
Net income 20.53B 216M 189M 174M 162M 307M 312M 2.09B 814M 10.13B 812M 795M 35.02B 23.22B 245M 214M 197M 183M 347M 353M 2.37B 920M 11.46B 919M 899M 39.61B
Net Debt -39.29B -414M -362M -334M -309M -588M -597M -4B -1.56B -19.39B -1.55B -1.52B -67.03B -37.12B -391M -342M -315M -292M -555M -564M -3.78B -1.47B -18.32B -1.47B -1.44B -63.32B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
08/07/26 2,223.70 -1.82% 337,287
07/07/26 ₹2,264.90 -0.26% 770,737
06/07/26 ₹2,270.90 +2.71% 600,450
03/07/26 ₹2,211.00 +0.68% 632,010
02/07/26 ₹2,196.00 +1.58% 526,651
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,264.90INR
Average target price
2,497.27INR
Spread / Average Target
+10.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock